Amiloid Protein Birikiminin Alzheimer ve Akdeniz Ateşi Hastalığındaki Rolü
Özet
Yanlış katlanmış proteinlerin dokularda birikmesiyle karakterize olan amiloidoz, Alzheimer Hastalığı (AH) ve Ailesel Akdeniz Ateşi (FMF) patogenezinde anahtar bir rol oynamaktadır. Amiloid yapılar canlılarda melanozom fonksiyonları ve hafıza oluşumu gibi normal hücresel süreçlerde yer alsa da, şaperon yetersizliği veya mutasyonlar nedeniyle birikerek toksisiteye yol açabilir. AH'de, amiloid öncü proteininin (APP) patolojik bölünmesiyle oluşan beta-amiloid (Aβ) peptitleri ve hiperfosforile tau proteinleri, mikrotübül bütünlüğünü ve aksonal taşımayı bozarak mitokondriyal hasara ve sinaps kaybına neden olur. Güncel araştırmalar, geleneksel Aβ hipotezinin ötesinde kalsiyum homeostazı bozukluğu, oksidatif stres ve glial aktivasyonun da nörodejenerasyonu tetiklediğini göstermektedir. Diğer taraftan FMF, MEFV geni mutasyonlarından kaynaklanan ve tekrarlayan inflamasyon ataklarıyla seyreden kalıtsal bir hastalıktır. FMF'nin en ciddi komplikasyonu olan AA tipi amiloidozda, karaciğer tarafından üretilen serum amiloid A (SAA) proteininin böbreklerde birikmesi, proteinüri, nefrotik sendrom ve ilerleyici böbrek yetmezliği ile sonuçlanır. Amiloidoz tanısında Kongo kırmızısı boyama yöntemi çift kırılmalı boyama özelliğiyle temel bir adım olsa da, doğru tedavi stratejisinin belirlenmesi için immünohistokimya ve kütle spektrometrisi ile spesifik amiloid protein tiplemesinin yapılması zorunludur.
Amyloidosis, characterized by the accumulation of misfolded proteins in tissues, plays a key role in the pathogenesis of Alzheimer's Disease (AD) and Familial Mediterranean Fever (FMF). Although amyloid structures are involved in normal cellular processes such as melanosome functions and memory formation in living organisms, they can cause toxicity by accumulating due to chaperone insufficiency or mutations. In AD, beta-amyloid (Aβ) peptides formed by the pathological cleavage of amyloid precursor protein (APP) and hyperphosphorylated tau proteins disrupt microtubule integrity and axonal transport, leading to mitochondrial damage and synapse loss. Current research shows that beyond the traditional Aβ hypothesis, calcium homeostasis dysregulation, oxidative stress, and glial activation also trigger neurodegeneration. On the other hand, FMF is a hereditary disease characterized by recurrent inflammation attacks, originating from mutations in the MEFV gene. In AA-type amyloidosis, the most serious complication of FMF, the accumulation of serum amyloid A (SAA) protein produced by the liver in the kidneys results in proteinuria, nephrotic syndrome, and progressive kidney failure. Although Congo red staining is a fundamental step in the diagnosis of amyloidosis with its birefringence property, specific amyloid protein typing via immunohistochemistry and mass spectrometry is mandatory to determine the correct treatment strategy.
Referanslar
Manning MC, Chou DK, Murphy BM, et al. Expert Review Stability of Protein Pharmaceuticals: An Update. Pharmaceutical Research. 2010;4:544-575.
Stollar EJ, Smith DP, Stollar E. Uncovering protein structure. Essays in Biochemistry. 2020;64:649–680.
Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annual Review Biochemistry. 2006;75:333–366.
Uversky VN. Dancing protein clouds: The strange biology and chaotic physics of intrinsically disordered proteins. Journal of Biological Chemistry. 2016;291(13):6681–6688.
Jain N, Chapman MR. Bacterial functional amyloids: Order from disorder. Biochimica et Biophysica Acta-Proteins and Proteomics. 2019;1867(10):954–960.
Pessayre D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Seminars in Liver Disease. 2001;5(21):67–69.
Li J, McQuade T, Siemer AB, et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell. 2012;150(2):339–350.
Cuddy SAM, Falk RH. Amyloidosis as a Systemic Disease in Context. Canadian Journal of Cardiology. 2020;36(3):396–407.
Chuang E, Hori AM, Hesketh CD, Shorter J. Amyloid assembly and disassembly. Journal of Cell Science. 2018;23;131.
Baiardi S, Rossi Ma, Capellari S, et al. Recent Advanced in Histo-molecular pathology of human prion disease. Brain Pathology. 2019;29:278–300.
Kaku M, Berk JL. Neuropathy Associated with Systemic Amyloidosis. Seminars in Neurology. 2019;39:578–588.
Lee SW, Choi H, Lee G, et al. Conformation Control of Amyloid Filaments by Repeated Thermal Perturbation. ACS Macro Letters. 2021;10(12):1549–1554.
Hazenberg BPC. Amyloidosis: A Clinical Overview. Rheumatic Disease Clinic of North America. 2013;39(2):323–345.
Ghiso J, Frangione B. Amyloidosis and Alzheimer’s disease. Advanced Drug Delivery Reviews. 2002;54(12):1539–1551.
Siligato R, Gembillo G, Calabrese V, et al. Amyloidosis and glomerular diseases in familial mediterranean fever. Med. 2021;57(10):1049.
Burns A, Iliffe S. Alzheimer’s disease. BMJ. 2009; 338(7692):467–471.
Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. Alzheimer’s & Dementia. 2016;12(6):719–732.
Ballatore C, Lee VMY, JQ T. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Neuroscience. 2007;8:663–672.
Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid β-peptide. Nature Reviews Molecular Cell Biology. 2007;8(2):101–112.
Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron. 2005;48(6):913–922.
Selkoe DJ. Alzheimer ’ s disease : Genes , proteins , and therapy. Physiciological Reviews. 2018;81(2001):4110.
Wälti MA, Ravotti F, Arai H, et al. Atomic-resolution structure of a disease-relevant Aβ(1-42) amyloid fibril. Proceeding National Academy of Sciences. 2016;113(34):4976–4984.
Nikolac Perkovic M, Pivac N. Genetic Markers of Alzheimer’s Disease. Advanced in Experimental Medicine and Biology. 2019;1192:27–52.
Zou K, Kim D, Kakio A, et al. Amyloid β-protein (Aβ)1-40 protects neurons from damage induced by Aβ1-42 in culture and in rat brain. Journal of Neurochemistry. 2003;87(3):609–619.
Holtzman DM, Bales KR, Paul SM, DeMattos RB. Aβ immunization and anti-Aβ antibodies: Potential therapies for the prevention and treatment of Alzheimer’s disease. Advanced Drug Delivery Reviews. 2002;54(12):1603–1613.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356.
Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer’s disease: An emperor in need of clothes. Nature Neuroscience Journal. 2012;15(3):349–357.
Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nature Medicine. 1996;2(8):864–70.
Hecimovic S, Wang J, Dolios G, et al. Mutations in APP have independent effects on Aβ and CTFγ generation. Neurobiology of Disease. 2004;17(2):205–218.
Li NM, Liu KF, Qiu YJ, et al. Mutations of beta-amyloid precursor protein alter the consequence of Alzheimer’s disease pathogenesis. Neural Regeneration Research. 2019;14(4):658–665.
Kumar-Singh S, Theuns J, Broeck B Van, et al. Mean Age of Onset of Familal Alzheimer Disease Caused by Presenilin Mutations Correlates With Both Increased Aβ42 and Decreased Aβ42. Human Mutation. 2006;27(7):686–695.
Bateman RJ, Xiong C, S BTL, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease. The New England Journal of Medicine. 2012;367(9):795–804.
Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease. Neurology. 2014;83(3):253–260.
Lesné S, Ming TK, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440(7082):352–357.
Dumanchin C, Camuzat A, Campion D, et al. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Human Molecular Genetic. 1998;7(11):1825–1829.
Ming J, Shepardson N, Yang T, et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. PNAS. 2011;108(14):5819–5824.
Götz J, Chen F, Van Dorpe J, et al. Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils. Science. 2001;293(5534):1491–1495.
Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293(5534):1487–1491.
Zempel H, Thies E, Mandelkow E, et al. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neuroscience. 2010;30(36):11938–11950.
Wang L, Li N, Shi FX, et al. Upregulation of AMPK Ameliorates Alzheimer’s Disease-Like Tau Pathology and Memory Impairment. Molecular Neurobiology. 2020;57(8):3349–3361.
Josepha J, Shukitt-Hale B, Denisova NA, et al. Copernicus revisited: Amyloid beta in Alzheimer’s disease. Neurobiology of Aging. 2001;22(1):131–146.
Lee HG, Zhu X, Castellani RJ, et al. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. Journal of Pharmacology and Experimental Theraupetic. 2007;321(3):823–829.
Herrup K. The case for rejecting the amyloid cascade hypothesis. Nature Neuroscience. 2015;18(6):794–9.
Mullane K, Williams M. Alzheimer’s disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochemical Pharmacology. 2018;158:359–75.
Sahil K, Barve KH, S KM. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Current Neuropharmacology. 2020;18:1106–1125.
Flannery PJ, Trushina E. Mitochondrial dynamics and transport in Alzheimer’s disease. Molecular and Cellular Neuroscience. 2019;98:109–20.
Swerdlow RH. Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2018;62:1403–1416.
Labbé K, Murley A, Nunnari J. Determinants and functions of mitochondrial behavior. Annual Review Cell and Developmental Biology. 2014;30(1):357–91.
Sheng Z-H, Cai Q. Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Neurosciences. 2012;13:77–93.
Misko A, Jiang S, Wegorzewska I, Milbrandt J, Baloh RH. Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. Journal of Neuroscience. 2010;30(12):4232–4240.
Picone P, Nuzzo D, Giacomazza D, Di Carlo M. β-Amyloid Peptide: the Cell Compartment Multi-faceted Interaction in Alzheimer’s Disease. Neurotoxicity Research. 2020;37(2):250–263.
Hansson Petersen CA, Alikhani N, Behbahani H, et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proceedings of National Academy of Science. 2008;105(35):13145–13150.
Calkins MJ, Manczak Ma, MAo P, et al. Impaired Mitochondrial Biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Human Molecular Genetic. 2011;20:4515–4529.
Zhang L, Trushin S, Christensen TA, et al. Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane. Neurobiological Disease. 2018;114:1–16.
De Strooper B, Karran E. The Cellular Phase of Alzheimer’s Disease. Cell. 2016;164(4):603–615.
Çakan M, Aktay Ayaz N, Keskindemirci G, et al. Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections. Clinical Rheumatology. 2020;39(1):249–253.
Shohat M, Halpern GJ. Familial mediterranean fever-a review. Genetics in Medicine. 2011;13(6):487–498.
Portincasa P. Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare. Current Medicinal Chemistry. 2015;23(1):60–86.
Akar S, Cetin P, Kalyoncu U, et al. Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients. Arthritis Care & Research. 2018;70(7):1090–1094.
Varan Ö, Kucuk H, Babaoglu H, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Modern Rheumatology. 2019;29(2):363–366.
Ihne S, Morbach C, Sommer C, et al. Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease. Deutsches Arzteblatt International. 2020;117(10):159–166.
Yonem O, Bayraktar Y. Secondary amyloidosis due to FMF. Hepatogastroenterology. 2007;54(76):1061–1065.
Stojanovic KS, Georgin-Lavialle S, Grateau G. Amylose AA. Néphrologie & Thérapeutique. 2017;13(4):258–264.
Andronesi AG, Ismail G, Gherghiceanu M, et al. Familial mediterranean fever-associated renal amyloidosis: Case report and review of the literature. Romaninan Journal of Morphology and Embryology. 2019;60(4):1299–1303.
Schwartz MM, Korbet SM, Lewis EJ. Immunotactoid glomerulopathy. Journal of American Society of Nephrology. 2002;13(5):1390–1397.
Ozdogan H, Ugurlu S. Familial Mediterranean Fever. Presse Medical. 2019;48:61–76.
Bellotti V, Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. Current Opinion in Structural Biology. 2008;18(6):771–779.
van der Hilst JCH, Yamada T, Op den Camp HJM, et al. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology. 2008;47(11):1651–1654.
Lannergård A, Larsson A, Kragsbjerg P, Friman G. Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. Scandinavian Journal of Clinical and Laboratory Investigation. 2003;63(4):267–272.
Ugurlu S, Egeli BH, Murat BI, et al. Soluble TREM-1 Levels in Familial Mediterranean Fever Related AA-Amyloidosis. Immunological Investigations. 2021;50(2–3):273–281.
Schulz H. Concerning Congo Red as a reagent for free acids. Cent fu’’r die Med Wissenchaften. 1886;29–30.
Unger PN, Zuckerbrod M, Beck GJ, et al. Study of the Dısappearance of Congo Red From the Blood of Non-Amyloıd Subjects and Patıents wıth Amyloıdosıs. Journal of Clinical Investigation. 1948;27:111-118.
Yakupova EI, Bobyleva LG, Vikhlyantsev IM, et al. Congo Red and amyloids: history and relationship. Bioscience Reports. 2019;39(1):20181415.
Leung N, Nasr SH, Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood. 2012;120(16):3206–3213.
Martini F, Buda G, De Tata V, et al. Different types of amyloid concomitantly present in the same patients. Hematology Reports. 2019;11(4):84–88.
